BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Knott David M Jr

Key Points

• Knott David M Jr cut its stake in BioCryst by 90.2%, selling 300,055 shares in Q3 and leaving 32,570 shares worth about $247,000.
• BioCryst beat expectations in its most recent quarter, reporting EPS of $1.12 versus a $0.07 consensus and revenue of $163.3 million, up 209.1% year‑over‑year.
• Institutional ownership is high at 85.88%, with large funds (Jump Financial, JPMorgan, Arrowstreet, Vanguard) increasing positions, and analysts holding a "Moderate Buy" consensus with an average price target of $19.64.

Knott David M Jr decreased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 90.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 32,570 shares of the biotechnology company's stock after selling 300,055 shares during the quarter. Knott David M Jr's holdings in BioCryst Pharmaceuticals were worth $247,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Jump Financial LLC grew its holdings in shares of BioCryst Pharmaceuticals by 805.0% during the 2nd quarter. Jump Financial LLC now owns 1,347,112 shares of the biotechnology company's stock valued at $12,070,000 after acquiring an additional 1,198,263 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of BioCryst Pharmaceuticals by 48.7% during the second quarter. JPMorgan Chase & Co. now owns 1,584,206 shares of the biotechnology company's stock worth $14,194,000 after acquiring an additional 518,623 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of BioCryst Pharmaceuticals by 326.1% during the second quarter. Russell Investments Group Ltd. now owns 440,249 shares of the biotechnology company's stock worth $3,945,000 after acquiring an additional 336,920 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in BioCryst Pharmaceuticals by 2,103.7% during the second quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company's stock valued at $38,336,000 after purchasing an additional 4,084,403 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in BioCryst Pharmaceuticals by 6.1% during the third quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company's stock valued at $165,393,000 after purchasing an additional 1,246,633 shares during the last quarter. Institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Down 0.2%

Shares of NASDAQ:BCRX opened at $8.48 on Friday. The company has a market cap of $2.13 billion, a price-to-earnings ratio of 7.07 and a beta of 0.74. The business has a 50 day moving average price of $7.23 and a 200 day moving average price of $7.41. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $1.05. The company had revenue of $163.28 million for the quarter, compared to the consensus estimate of $151.32 million. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The business's revenue was up 209.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.13) EPS. Analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Insiders Place Their Bets

In related news, insider Alane P. Barnes sold 21,773 shares of the business's stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $7.65, for a total value of $166,563.45. Following the sale, the insider owned 398,751 shares of the company's stock, valued at $3,050,445.15. The trade was a 5.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 5.10% of the company's stock.

Analyst Ratings Changes

BCRX has been the subject of a number of recent research reports. Royal Bank Of Canada cut their price target on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating for the company in a research note on Friday, January 30th. HC Wainwright boosted their price target on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a "buy" rating in a research note on Monday, December 15th. Evercore initiated coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an "outperform" rating and a $17.00 price objective on the stock. Finally, Weiss Ratings raised shares of BioCryst Pharmaceuticals from a "sell (d-)" rating to a "hold (c)" rating in a research report on Wednesday. Ten analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $19.64.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.